Today's Trend
Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares have increased modestly, although the latest analyst estimate revisions provide a mixed signal for investors.
- HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
- The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
- A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
- HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
- The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.
Overall, the retained Buy rating and expectation for a return to profitability may be supporting AXSM. However, the broad downward revisions—particularly the 19% cut to the FY2027 EPS forecast—suggest analysts see slower near-term earnings growth and could limit upside. The company’s current full-year consensus remains a loss of approximately $2.78 per share.